Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACTIVE: Injectable vs Oral Antipsychotics in Schizophrenia
NCT00330863Phase 4Completed
- Sponsor
- Northwell Health
- Start
- May 2006
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Northwell Health. Primary endpoint: Substantial Clinical Deterioration Measured by Psychotic Symptoms at 30 months. Started May 2006; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00330863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330863.